Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
← catalyst calendarNCT06117774 · readout in 1,340 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
404actual
Sites
204
Countries
Argentina, Australia, Austria +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-20 | actual | When the study began enrolling |
| Primary completion | 2030-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-20 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Limited Stage Small Cell Lung Cancer
- Small Cell Lung Cancer
Interventions
- Drug: Tarlatamab — also filed as AMG 757
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPFS as Determined by BICR
measured Up to approximately 6 years
OS Over the Whole Trial
measured Up to approximately 6 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed